Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT02269540 : A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A)
PhasePhase 0
AgesMin: 18 Years Max: 49 Years
Eligibility
Inclusion Criteria:

- DSM-IV diagnosis of current major depressive episode and major depressive disorder

- Hamilton Depression Rating Scale score of at least 20

Exclusion Criteria:

- Comorbid axis I or II disorders

- Antidepressant use in past 6 months

- Current use of herbal remedies

- Cigarette smoking

- Drug or medication use within past 8 weeks

- History of substance abuse/neurotoxin use

- History of psychotic symptoms

- History of CNS medical illness

- Current substance use

- Test positive on pregnancy test (women)
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT02269540      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740